AnPac Bio-Medical Science is a company with operations in the US and China focused on early cancer screening and detection.
A Malaysian client who had signed a $1.5 million purchase contract for AnPac Bio’s Model AP9080 cancer detection devices has paid the company’s first installment. AnPac Bio-Medical Science is a company with operations in the US and China focused on early cancer screening and detection.
The company’s patented, cutting-edge multi-cancer testing technology, known as Cancer Differentiation Analysis (CDA) Technology, serves as the foundation for the Model AP9080 cancer detection device.
This represents a significant milestone for the company, as it represents the first significant sale of its cancer detection device into Southeast Asia.
Additionally, it represents the company’s official entry into the global market for cancer detection devices as well as confirmation of AnPac Bio’s ground-breaking technology, stellar reputation, and ability to break into the sizable global market.
According to the terms of the purchase agreement, AnPac Bio will give the Malaysian customer its Model AP9080 cancer detection device, maintenance services, consumables, and equipment parts.
After the sale of the equipment, the company will continue to earn money from services, consumables, and equipment parts.
The Malaysian client intends to establish biomedical laboratories, acquire Laboratory Developed Test (LDT) certification, and perform paid cancer tests. Measuring biophysical characteristics in the blood serves as the foundation for the company’s CDA cancer detection technology.
It can detect a variety of cancer types at an early stage, is cost-effective and relatively easy to use, and offers high sensitivity and specificity, which are all significant advantages over traditional technologies. AnPac Bio was ranked first in the world for multi-cancer testing sample size in 2021, according to a report by the US marketing research company Frost & Sullivan.
AnPac Bio-Medical Science is a biotechnology company focusing on pre-cancer and cancer screening to develop early disease detection devices that are more accessible. AnPaC Bio aims to develop, distribute, and deploy this technology to change the way people think about screening.